

N Indices Value		Pts	Chg (%)
SENSEX	36033.73	(249.52)	(0.69)
NIFTY	11049.65	(80.75)	(0.73)
SGX NIFTY*	11068.50	2.00	0.02
DOW Jones	26076.89	(362.59)	(1.37)
S&P 500	2822.43	(31.10)	(1.09)
Nasdaq	7402.48	(64.02)	(0.86)
FTSE	7587.98	(83.55)	(1.09)
CAC	5473.78	(47.80)	(0.87)
DAX	13197.71	(126.77)	(0.95)
Shanghai Composite*	11237.61	(41.17)	(0.37)
Nikkei*	6034.40	11.60	0.19
Hang Seng*	11083.71	6.93	0.06

*As at 8.30 am

Most Active Call & Put Symbol	Strike Price	OI	Chg (%)
NIFTY	11500 CE	2968200	20.17
NIFTY	11000 PE	3760500	10.60

Commodity	Value	Pts	Chg (%)
NYMEX Crude (USD)	63.95	(0.55)	(0.85)
Brent Crude (USD)	68.50	(0.52)	(0.75)
Gold (INR)	29991	(34.00)	(0.11)
Silver (INR)	39072	(73.00)	(0.19)
Copper (INR)	450	(0.75)	(0.17)
Zinc (INR)	225	(4.10)	(1.79)
Cotton (INR)	20090	190.00	0.95

Currency	Value	Pts	Chg (%)
USD/Rupee	63.58	0.03	0.05
Euro/Rupee	78.95	(0.02)	(0.03)
Pound/Rupee	89.73	(0.28)	(0.31)
Euro /USD	1.24	0.00	0.24
Dollar Index	89.04	(0.12)	(0.14)

Volatility	Value	Pts	Chg (%)
CBOE VIX	14.79	0.95	6.86
India VIX	16.41	(1.48)	(8.27)

Interest Rates	Value	Bps change
India 10-Yr Yield	7.41%	1
US 10-Yr Yield	2.71%	1

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	5285.39	34631.47	352936.00
Advance (Nos)	748(25%)	416(24%)	NA
Declines (Nos)	2097(70%)	1383(71%)	NA
Unchanged	147(5%)	56(5%)	NA

Market Summary

The market ended on a negative note on Tuesday. The Market breadth was negative with more than 1 gainer for every 3 losers on BSE. 748 shares advanced whereas 2097 share declined and 147 shares were unchanged on BSE.

BSE Sensex plunged 250 points or (0.7%) to close at 36034. Nifty 50 was down 81 points or (0.7%) to settle at 11050. BSE Mid-Cap index lost 119 points or (0.7%) to settle at 17591. BSE Small-Cap index declined 256 points or (1.3%) to settle at 18874.

Top gainer in BSE Sensex were Coal India (1.7%), Hero Motocorp (1.3%), Sun Pharma (0.7%), SBI (0.6%) and HUL (0.2%) whereas top loser in BSE were Asian paints (2.2%), Kotak Mahindra (2.2%), Axis Bank (2.0%), Dr Reddys labs (1.9%) and Adani Ports (1.8%).

US markets closed largely negative, Dow Jones Industrial Average closed at 26077, declining 363 points (1.4%), S&P 500 was down 31 points (1.1%) to close at 2822 and Nasdaq lost 64 points (0.9%) to close at 7402.

European markets closed negative, FTSE declined 84 points (1.1%) to close at 7588, CAC was down 48 points (0.9%) to close at 5474 and DAX lost 127 points (1.0%) to close at 13198.

Macro News

- State Bank of India, raised interest rate on domestic bulk term deposits on Tuesday by 75-140 basis points with immediate effect, at a time when liquidity in the system is under strain. This is second hike in bulk deposit rates by SBI in a span of about two months. It had raised bulk term deposits by one per cent (100 basis points) in November 2017.

- Infrastructure companies have sought higher budgetary allocations to roads, rail, energy, metals and mining and, social infrastructure sectors in Budget 2019. Allocation of funds in the core Infrastructure sectors is expected get accelerated this year. Dedicated allocations for specified large infrastructure projects announced such as bullet trains, Bharat Mala, Sagar Mala, Smart Cities, inland waterways development, can also be made to expedite these projects.

- India has urged the European Union not to ban or blacklist any seafood exporter immediately after finding problems with just one consignment as this extreme step worked against the interests of all the stakeholders. EU had rejected a few Indian seafood consignments on quality issues and had increased sampling to 50% from 10% last year..

Institutional Activity	30-Jan	Cash Jan'2018
FII (INR Crs)		
Buy	6183	127192
Sell	6288	117487
Net	(106)	9705
DII (INR Crs)		
Buy	4636	87207
Sell	4918	88103
Net	(282)	(896)

FII Derivative Statistics (NSE)				
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)	Chg (%)
INDEX FUTURES	1513.56	2954.08	218543	9.16
INDEX OPTIONS	41753.60	40531.86	714712	2.77
STOCK FUTURES	10268.82	9582.30	1032502	1.83
STOCK OPTIONS	6199.24	6175.68	43241	37.98
Total	59735.22	59243.92		

Gainers & Losers		Price	Chg (%)
Gainers (INR)			
Coal India		305.70	1.71
Hero Motocorp		3688.50	1.33
Sun Pharma		591.30	0.72
SBI		312.85	0.56
HUL		1399.45	0.16
Losers (INR)			
Asian Paints		1128.90	(2.22)
Kotak Mahindra		1089.55	(2.15)
Axis Bank		593.40	(1.98)
Dr Reddys Labs		2312.00	(1.86)
Adani Ports		428.50	(1.84)

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	18873.58	(255.56)	(1.34)
S&P BSE Mid-Cap	17591.39	(118.91)	(0.67)
S&P BSE Auto	25956.89	(124.08)	(0.48)
S&P BSE BANKEX	30861.34	(264.46)	(0.85)
S&P BSE Capital Goods	20594.90	(75.24)	(0.36)
S&P BSE FMCG	10847.41	(36.26)	(0.33)
S&P BSE Healthcare	14799.78	(91.41)	(0.61)
S&P BSE IT	12697.25	(137.96)	(1.07)
S&P BSE Metals	15622.22	(98.86)	(0.63)
S&P Oil & Gas	16290.56	187.35	1.16

Key News

IOC Q3 net profit nearly doubles to INR 78.83 billion, beats estimates

IOC Ltd reported a Net profit of 97% to INR 78.83 billion (USD 1.24 billion) in the quarter ended December 31, from INR 39.95 billion a year earlier. Average gross refining margin improved to USD 8.28 per barrel in the April-December period from USD 7.36 per barrel in the year-ago period.

Piramal Enterprises Q3 net profit up 21% at INR 4.90 billion

Piramal Enterprises on Tuesday reported 21.37% rise in consolidated net profit to INR 4.90 billion for the December quarter on robust performance in financial services and pharmaceutical verticals. The company had posted a net profit of INR 4.04 billion in the year-ago period. Consolidated revenue from operations also rose to INR 28.58 billion for the quarter under review, against INR 23.41 billion in the same period a year ago. The company announced 22% growth in total revenues at INR 28.58 billion and 21% increase in net profit at INR 4.9 billion for the third quarter of 2017-18.

TVS Motor Q3 net up 16% to INR 1.55 bn on strong sales

TVS Motor's Profit After Tax (PAT) rose 16.3% to INR 1.55 billion in the quarter ended December 2017, from INR 1.33 billion in the corresponding quarter a year ago. The company reported a revenue growth of 23.5% for the quarter under review. Revenue excluding excise duty and GST grew to INR 36.85 billion in the quarter ended December 2017 from INR 29.84 billion in the year-ago quarter.

Divis to spend INR 300 crore on expansion plans in 2018

Drug firm Divis Laboratories is focussed on expanding capacities of existing plants, even as its proposed plant at Kakinada, Andhra Pradesh ran into rough weather. The company spent about INR 400 crore till December last year and will be spending another INR 300 crore on the expansion programme during the current year. The state government allotted 505 acres of land at Ontimamidi Village (Kona), Thondangi Mandal, East Godavari District, and gave the company advance possession of the land, pending procedural formalities.

International Data

Country	Data	Forecast	Previous
US	FOMC Statement	NA	NA

Sharad Avasthi

Head - Equity Research

sharad.avasthi@spagroupindia.com

Tel.: +91-022-42895600

Ext.206

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economicstimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
<ul style="list-style-type: none"> • Managing/co-managing public offering of securities • Investment banking/merchant banking/brokerage services • products or services other than those above • in connection with research report 	No
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

For More Information Visit Us At : www.spasecurities.com

SPA CAPITAL SERVICES LIMITED

Investment Advisory services,
AMFI Reg. No. ARN-0007

SPA Capital Advisors Limited

SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825

SPA COMTRADE PRIVATE LIMITED

SPA INSURANCE BROKING SERVICES LTD.

Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03

SPA Securities Ltd

NSE Cash
NSE Future & Option
NSE Currency Derivatives
BSE Cash
BSE Currency Derivatives
MCX-SX Cash
MCX-SX Future & Option
MCX-SX Currency Derivatives
Mutual Fund
CDSL DP
NSDL DP
SEBI Research Analyst

SEBI Reg. Nos.

INB231178238
INF231173238
INE231178238
INB011178234
INE011178234
INB261178231
INF261178231
INE261178238
ARN 77388
IN-DP-CDSL-485-2008
IN-DP-NSDL-316-2009
INH100002615